United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use
(NASDAQ:BMRA) IRVINE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced today announced that the United Arab Emirates (UAE) Ministry of Health and Prevention has approved its Fortel® Kidney Test for home use. This important regulatory milestone expands access to accurate, easy-to-use diagnostic tools supporting early identification of kidney damage in high-risk populations.
Related Questions
How will the UAE approval of the Fortel® Kidney Test affect Biomerica's revenue forecasts and earnings guidance?
What is the potential market size and growth trajectory for home-use kidney diagnostics in the UAE and broader Middle East region, and how does this position BMRA against competitors like Abbott and Roche?
What are the timelines and regulatory hurdles for further international approvals, and how might those shape the stock's valuation over the next 12‑24 months?